Efficacy and safety of a modified daratumumab/bortezomib/dexamethasone regimen using once weekly bortezomib in relapsed refractory multiple myeloma

The combination of daratumumab (dara), subcutaneous (SC) bortezomib twice weekly, and dexamethasone (dex) [Dara-Vd] has become a common treatment for patients with relapsed and/or refractory multiple myeloma (MM) after the CASTOR trial data led to its inclusion in the NCCN guidelines. A common and notable non-hematologic adverse effect causing dose modifications, delays, or discontinuation of bortezomib in this regimen has been peripheral neuropathy (PN). This could impact a patient's quality of life or lead to suboptimal therapy.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research